Efficacy and safety of Ningmitai Capsule in treatment towards type III prostatitis: A randomized, double-blind, placebo-control clinical trial / 中草药

ABSTRACT

Objective: To evaluate the efficacy and safety of Ningmitai Capsule in the treatment towards type III prostatitis. Methods A randomized, double-blind, placebo-control clinical trial was conducted. A total of 50 patients diagnosed as type III prostatitis were divided into two groups with the ratio of 11. Patients of the trial group were treated with Ningmitai Capsule at the dose of four grain tid for 4 weeks, and patients of the control group were given placebo in the same way. The efficacy was evaluated by the NIH chronic prostatitis symptom index (NIH-CPSI) while safety-evaluation was evaluated by adverse events, results of urine routine examinations and hepatorenal-function tests. Results:After 4-week treatment, NIH-CPSI total scores were 23.96 ± 1.30 before treatment, and reduced to 16.04 ± 1.66 (P < 0.001). To the contrary, for all these scores, no significant statistical differences exist in placebo-control group. Pain-symptom scores, micturition-symptom scores and QOL scores were all statistically reduced in the trial group. No significant adverse events occurred in all patients who completed the study. Conclusion:Ningmitai Capsule is effective and safe in the treatment of type III prostatitis.